跳至主要内容
临床试验/NCT02599311
NCT02599311Unknown3 期

The Clinical Efficacy of Pelvic Organ Prolapse Surgery

Peking University People's Hospital1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2015年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
1,000
试验地点
1
主要终点
the objective recurrent rate

研究概览

简要总结

One thousand patients with stage>2 POP are recruited. The patients are all received surgeries,such as transvaginal synthetic mesh surgery, the sacral fixation, tissue repair surgery and colpocleisis. The patients with POP who have not undergone surgery are excluded. Postoperatively, the investigators investigate the indications and clinical efficacy of pelvic organ prolapse surgery.

详细描述

Postoperatively, the investigators analyze the patients' subjective and objective recurrent rates. The investigators compare the quality of life by filling out the preoperative and postoperative scoring questionnaires (PISQ 12, PFDI-20, PFIQ-7).The electrical physiological changes will be focused on. The investigators also use Overactive Bladder Symptom Score(OABss) to assess the lower urinary tract symptoms.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • The patients with stage>2 POP are recruited.The patients are all received surgeries, which include transvaginal synthetic mesh surgery, the sacral fixation, tissue repair surgery and colpocleisis.

排除标准

  • The patients with POP who have not undergone surgery are excluded.

研究组 & 干预措施

the efficacy

Other

transvaginal synthetic mesh

干预措施: transvaginal synthetic mesh (Device)

the rate of the LUTS

Other

We use Tolterodine to improve patients' LUTS

干预措施: Tolterodine (Drug)

结局指标

主要结局

the objective recurrent rate

时间窗: one year after surgery

The objective recurrence means postoperative stage≥2 (POP-Q) in any compartment.

次要结局

  • the quality of life questionnaires(one year after surgery)
  • the rate of the lower urinary tract symptoms(one year after surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验